• Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment 

      Madssen, Torfinn Støve; Thune, Inger; Flote, Vidar Gordon; Lundgren, Steinar; Bertheussen, Gro Falkener; Frydenberg, Hanne; Wist, Erik; Schlichting, Ellen; Schäfer, Hartmut; Fjøsne, Hans Erikssønn; Vettukattil, Muhammad Riyas; Lømo, Jon; Bathen, Tone Frost; Giskeødegård, Guro F. (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-11-07)
      <p><i>Background</i>: Breast cancer treatment has metabolic side effects, potentially affecting risk of cardiovascular disease (CVD) and recurrence. We aimed to compare alterations in serum metabolites and lipoproteins during treatment between recipients and non-recipients of chemotherapy, and describe metabolite profiles associated with treatment-related weight gain.</p> <p><i>Methods</i>: This ...
    • Peripheral blood cells inform on the presence of breast cancer: A population‐based case–control study 

      Dumeaux, Vanessa; Ursini‐Siegel, Josie; Flatberg, Arnar; Fjøsne, Hans Erikssønn; Frantzen, Jan Ole; Holmen, Marit Muri; Rodegerdts, Enno; Schlichting, Ellen; Lund, Eiliv (Journal article; Tidsskriftartikkel; Peer reviewed, 2014-06-14)
      Tumor–host interactions extend beyond the local microenvironment and cancer development largely depends on the ability of malignant cells to hijack and exploit the normal physiological processes of the host. Here, we established that many genes within peripheral blood cells show differential expression when an untreated breast cancer (BC) is present, and harnessed this fact to construct a 50-gene ...
    • Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel 

      Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Skjønsberg, Gudbrand; Aas, Turid; Schlichting, Ellen; Fjøsne, Hans Erikssønn; Nysted, Arne; Lillehaug, Johan R.; Lønning, Per Eystein (Journal article; Tidsskriftartikkel; Peer reviewed, 2011)
      TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wildtype p53 protein activity. Here, we explored the predictive and prognostic value of TP53 and CHEK2 mutation status together with MDM2 SNP309 genotype in stage III breast cancer ...